108 related articles for article (PubMed ID: 35138351)
1. Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
Bommareddy K; Hamade H; Lopez-Olivo MA; Wehner M; Tosh T; Barbieri JS
JAMA Dermatol; 2022 Mar; 158(3):275-282. PubMed ID: 35138351
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Farquhar C; Lee O; Toomath R; Jepson R
Cochrane Database Syst Rev; 2003; (4):CD000194. PubMed ID: 14583916
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Brown J; Farquhar C; Lee O; Toomath R; Jepson RG
Cochrane Database Syst Rev; 2009 Apr; (2):CD000194. PubMed ID: 19370553
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism.
Vargas-Mora P; Morgado-Carrasco D
Actas Dermosifiliogr (Engl Ed); 2020 Oct; 111(8):639-649. PubMed ID: 32571540
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Farquhar C; Lee O; Toomath R; Jepson R
Cochrane Database Syst Rev; 2001; (4):CD000194. PubMed ID: 11687072
[TBL] [Abstract][Full Text] [Related]
10. Green tea (Camellia sinensis) for the prevention of cancer.
Filippini T; Malavolti M; Borrelli F; Izzo AA; Fairweather-Tait SJ; Horneber M; Vinceti M
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005004. PubMed ID: 32118296
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
12. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.
Kunath F; Jensen K; Pinart M; Kahlmeyer A; Schmidt S; Price CL; Lieb V; Dahm P
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD003506. PubMed ID: 31194882
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Lee O; Farquhar C; Toomath R; Jepson R
Cochrane Database Syst Rev; 2000; (2):CD000194. PubMed ID: 10796700
[TBL] [Abstract][Full Text] [Related]
14. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
Rosenberg JE; Jung JH; Edgerton Z; Lee H; Lee S; Bakker CJ; Dahm P
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013641. PubMed ID: 32813279
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy after surgery for epithelial ovarian cancer.
Saeaib N; Peeyananjarassri K; Liabsuetrakul T; Buhachat R; Myriokefalitaki E
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012559. PubMed ID: 31989588
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
[TBL] [Abstract][Full Text] [Related]
17. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Jung JH; McCutcheon KA; Borofsky M; Young S; Golzarian J; Reddy B; Shin TY; Kim MH; Narayan V; Dahm P
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012867. PubMed ID: 33368143
[TBL] [Abstract][Full Text] [Related]
18. Dietary glycemic index, glycemic load and cancer risk: a meta-analysis of prospective cohort studies.
Long T; Liu K; Long J; Li J; Cheng L
Eur J Nutr; 2022 Jun; 61(4):2115-2127. PubMed ID: 35034169
[TBL] [Abstract][Full Text] [Related]
19. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.
Drost FH; Osses DF; Nieboer D; Steyerberg EW; Bangma CH; Roobol MJ; Schoots IG
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012663. PubMed ID: 31022301
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
